Open AccessShould we use the oral selective IP receptor agonist selexipag off‐label in children with pulmonary arterial hypertension?
Author(s) -
Koestenberger Martin,
Hansmann Georg
Publication year - 2018
Publication title -
pulmonary circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.791
H-Index - 40
ISSN - 2045-8940
DOI - 10.1177/2045894018793580
Subject(s) - medicine , prostacyclin , agonist , pharmacology , pulmonary hypertension , receptor
We discuss the currently available data on the use of the prostacyclin mimetic selexipag in children and adolescents with pulmonary arterial hypertension (PAH). Future indications may include transitioning from intravenous prostacyclin/prostacyclin analog to oral selexipag, and vice versa, or adding selexipag as a third oral PAH‐targeted agent in children not responding well to dual PAH therapy.